Additionally, small-molecule drugs targeting the NF-κB pathway, such as BAY 11–7082 and Parthenolide, have demonstrated potential in inhibiting disc degeneration-related inflammatory responses (112). The gene discussed is NFKB1; the disease is intervertebral disk degenerative disorder.